SCHEMBL25949176

SCHEMBL25949176

CCCc1ccc(C(=O)O)cc1CNc1cncnc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 1/20 0.41
▸ HCAR3 P49019 5/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ PLEC Q15149 1/20 0.39
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ HCAR2 Q8TDS4 1/20 0.37
▸ TRPV1 Q8NER1 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30340070 0.89 AR (0.42) ARALDH1A1TRPV1SMN1; SMN2
SCHEMBL24070745 0.83 KDM4C (0.47) ARKDM4EALDH1A1CA1CA2
SCHEMBL25949177 0.80 ACE2 (0.44) ARHCAR3KDM4EALDH1A1CA1
SCHEMBL566628 0.77 RXRA (0.47) KDM4EALDH1A1GAAMAPTTHRB
SCHEMBL14922850 0.75 ALDH1A1 (0.48) KDM4EALDH1A1GAAMAPTTHRB
SCHEMBL23095784 0.72 KMT2A (0.53) HCAR3KDM4EALDH1A1GAAMAPT
SCHEMBL13535960 0.70 EPHX2 (0.51) KDM4EALDH1A1GAAMAPTTHRB
SCHEMBL8984332 0.70 ACE2 (0.49) KDM4EALDH1A1GAAMAPTTHRB
SCHEMBL80902 0.69 RXRA (0.52) KDM4EALDH1A1GAAMAPTTHRB
SCHEMBL23501594 0.68 POLB (0.44) KDM4EALDH1A1GAAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697485-B Benzylamine derivatives as DDR inhibitors 奇斯药制品公司 2025-03-14 — — CN disclosed
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-20 — — US disclosed
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-20 — — US disclosed
EP-4157447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-04-05 — — EP disclosed
CN-115697485-A Benzylamine derivatives as DDR inhibitors 奇斯药制品公司 2023-02-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS DDR2, DDR1, DDRGK1 AR 1797/4885HCAR3 3050/4885KDM4E 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback